PTW-002 /g

Small molecule

PTW-002 /g is one of 13 small molecule programs targeting Recessive Dystrophic Epidermolysis Bullosa. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recessive Dystrophic Epidermolysis BullosaActive, not recruiting

Recessive Dystrophic Epidermolysis BullosaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Recessive Dystrophic Epidermolysis Bullosa

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 1

1 2

Mesenchymal Stromal Cells

Mario Negri Institute for Pharmacological Research

Phase 2

1 3

Garamycin

SSchering-Plough

Phase 1

2 4

Kepivance

SSwedish Orphan Biovitrum

Phase 1

1 5

Prograf

VVeloxis Pharmaceuticals

Phase 1

1 6

Ativan

BBausch Health Americas, Inc.

Phase 1

1 7

Campath

GGenzyme, a Sanofi Company

Phase 1

1 8

Busulfex

Akero Therapeutics

Phase 1

1 9

Accutane

CConrado Roberto Hoffmann Filho

Phase 1

1 10

EB-101

AAbeona Therapeutics, Inc

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Recessive Dystrophic Epidermolysis Bullosa1 trial

Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene

Unknown status·PPhoenicis Therapeutics·Phase 1/2·NCT05529134·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PTW-002 /g. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PTW-002 /g compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PTW-002 /g. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Phoenicis Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: PPhoenicis Therapeutics

PTW-002 /g

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Recessive Dystrophic Epidermolysis Bullosa1 trial

References

Drug Info

Quick Facts

Related News